Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MariMed Inc. (MRMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, quarterly updates, and annual reports filed with the U.S. Securities and Exchange Commission. As a multi-state cannabis operator and cannabis consumer packaged goods company, MariMed uses these filings to report on its financial condition, operating performance, and material events.
Investors can review documents such as Form 8-K current reports, where MariMed furnishes press releases announcing quarterly results and other significant developments. These filings typically reference revenue, gross margin, net income or loss, and non-GAAP measures like Adjusted EBITDA and non-GAAP gross margin, along with management’s discussion of how these metrics are used to evaluate the business.
Through its periodic reports, MariMed also describes risks, uncertainties, and factors that could affect future performance, including changes in customer spending, regulatory approvals, and integration of acquired operations. Forward-looking statements in these filings are accompanied by cautionary language directing readers to additional risk discussions in the company’s reports.
On Stock Titan, each new MariMed filing is captured from the SEC’s EDGAR system and paired with AI-powered summaries that highlight key points, such as updates to financial results, explanations of non-GAAP metrics, and descriptions of material events. Users can quickly scan these summaries, then open the full filing for deeper review. This page also helps track items like insider and executive-related disclosures when they are reported on SEC forms, giving a structured view of MariMed’s regulatory reporting history.
MariMed Inc. reported fourth quarter and full year 2025 results showing modest revenue growth but lower margins and profitability. Full year revenue was $159.8 million, up slightly from $157.7 million in 2024, while GAAP net loss widened to $14.5 million from $12.4 million. Non-GAAP Adjusted EBITDA was $16.9 million versus $19.3 million, marking a sixth consecutive year of positive Adjusted EBITDA but at a lower margin. In Q4 2025, revenue rose to $41.7 million from $38.9 million, with GAAP gross margin declining to 25%. Management highlighted 11% wholesale revenue growth, distribution reaching 85% of dispensaries in core markets, and leading edible rankings for Betty’s Eddies. The company also restructured $14.725 million of Series B preferred stock, extending the weighted average maturity by 4.6 years to reduce near-term refinancing risk and support liquidity.
MARIMED INC. Chief Operating Officer Timothy Shaw exercised 21,667 restricted stock units into an equal number of common shares on March 7, 2026, at a stated price of $0.00 per share. These RSUs were originally granted on March 7, 2023 and are now fully vested with no remaining units under that grant.
To cover tax withholding from this vesting, 7,508 common shares were withheld at $0.084 per share, reducing his directly held common stock to 9,351,177 shares. Separately, 2,000,000 common shares are held indirectly by the Shaw Family Trust for the benefit of his children; his spouse serves as trustee, and he disclaims beneficial ownership of those trust shares.
MariMed Inc. President and CEO Jon R. Levine reported equity compensation activity involving restricted stock units and common shares. He exercised 23,333 restricted stock units into 23,333 shares of common stock at a stated price of $0.0000 per share, reflecting a derivative exercise/conversion.
To cover tax withholding obligations from this RSU vesting, 8,085 common shares were withheld at $0.0840 per share, leaving him with 21,151,448 shares of common stock held directly after these transactions. An additional 6,684,640 common shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children, and he disclaims beneficial ownership of those trust-held securities.
MariMed Inc. Chief Commercial Officer Ryan Crandall reported equity compensation activity involving restricted stock units (RSUs) that convert to common shares on a one-for-one basis. On the reported date, 12,500 RSUs were exercised into 12,500 shares of common stock at no cash exercise price.
To satisfy tax withholding obligations tied to this RSU vesting, 4,332 common shares were withheld by the company. After these transactions, Crandall’s direct ownership in MariMed common stock stood at 875,683 shares.
MARIMED INC. Chief Operating Officer Timothy Shaw reported equity compensation activity involving restricted stock units (RSUs) and common shares. On March 1, 2026, 65,000 RSUs were exercised, converting on a one-for-one basis into 65,000 shares of common stock at a stated price of $0.0000 per share.
To cover tax withholding obligations tied to this RSU vesting, 22,523 shares of common stock were withheld by the company at $0.0848 per share, reducing the net shares retained. After these transactions, Shaw directly held 9,337,018 shares of MARIMED common stock.
The filing also notes 2,000,000 shares of common stock held indirectly by the Shaw Family Trust. Shaw’s spouse is the trustee, and the trust benefits their children; Shaw disclaims beneficial ownership of these trust-held securities. The RSUs involved were granted on September 1, 2023, with remaining units scheduled to vest on September 1, 2026 under an award agreement.
MariMed Inc. entered into a restructuring agreement with Navy Capital that cancels its prior Series B preferred stock obligation tied to a potential cash payment of approximately $14.2 million. In its place, MariMed issued two new promissory notes totaling $8,000,000 and new Series B preferred shares.
The notes comprise $2,000,000 due on March 1, 2028 at 8% interest and $6,000,000 due on March 1, 2031 at 10%, with a possible rate reduction if the first note is repaid within six months. MariMed also issued 26,900,000 non-voting New Series B Convertible Preferred shares with a liquidation preference of $6,725,000 that rank senior to common stock for dividends and liquidation and are convertible into common stock under specified price and VWAP conditions.
MariMed Inc. Chief Financial Officer Mario Pinho reported routine equity award activity. On January 15, 2026, 49,995 restricted stock units converted into 49,995 shares of common stock at a price of $0 per share, increasing his directly held common stock to 294,809 shares. As part of the same vesting event, 17,324 common shares were withheld by MariMed at $0.096 per share to satisfy tax withholding obligations, leaving Pinho with 277,485 common shares held directly after the withholding.
The underlying restricted stock unit award was originally granted on July 15, 2024 and continues to vest over time, with remaining installments scheduled on July 15, 2026, January 15, 2027 and July 15, 2027. Following this transaction, Pinho directly holds 149,985 restricted stock units, each convertible into one share of common stock.
MariMed Inc.'s Chief Financial Officer reported equity compensation activity involving restricted stock units (RSUs) that vested and converted into common shares. On 12/31/2025, 53,571 RSUs were converted into the same number of shares of common stock at an effective price of $0, increasing his directly held position to 260,538 shares. On the same date, 15,724 shares were withheld and disposed of at $0.0891 per share to cover tax obligations tied to the vesting, leaving the officer with 244,814 directly owned shares afterward. The RSU grant, originally awarded on February 18, 2025, is now fully vested with no remaining unvested units.
MariMed Inc. director Eva Selhub reported an equity compensation transaction involving restricted stock units (RSUs). On December 15, 2025, 166,985 RSUs converted into the same number of shares of MariMed common stock at a stated price of $0, reflecting the non-cash nature of the award. The RSUs were originally granted on December 5, 2025 and vested in full on December 15, 2025 under an award agreement between MariMed and Selhub. According to the filing, these RSUs were granted in lieu of cash for a portion of her fees for serving on the Board of Directors, and she beneficially owned 482,671 shares of common stock directly after the transaction.
MariMed Inc.'s Chief Financial Officer, Mario Pinho, reported equity award activity involving restricted stock units (RSUs) and common shares. On December 15, 2025, 16,075 RSUs were converted into the same number of shares of common stock at a stated price of $0, reflecting the vesting of a stock-based award.
To cover tax withholding obligations from this vesting, 4,719 shares of common stock were withheld by MariMed at a price of $0.1071 per share. After these transactions, Pinho directly owned 206,967 shares of MariMed common stock. All RSUs from the May 9, 2025 grant are now fully vested, with no unvested units remaining under that award.